Canagliflozin attenuates cardiac magnetic resonance (CMR)-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial
Primary result · ECVResult — go to the resultAdjusted mean difference −3.67 % 95% CI −5.33 to −2.01Authors' conclusion
This study demonstrates that 26 weeks of canagliflozin significantly reduces myocardial fibrosis, as assessed by CMR-derived ECV, in individuals with type 2 diabetes at high cardiovascular risk, providing imaging evidence for SGLT2 inhibitor cardiovascular protection mechanisms.
Study context
- Population
- High-cardiovascular-risk adults (18–75 years) with T2D (HbA1c 53.0–91.3 mmol/mol [7.0–10.5%]) and left ventricular ejection fraction (LVEF) >50%, Zhongshan Hospital, Fudan University (August 2022 to November 2024)randomised 1:1
- Participants
- 45 adults
- Comparison
- Canagliflozin vs sitagliptin
- Canagliflozinn = 23
- Sitagliptinn = 22reference
- Primary endpoint
- Change in CMR-quantified extracellular volume (ECV)
- Follow-up
- 26 weeks
Methodological detailsopen-label, parallel, outcome assessors and data analysts blinded
- Open-label
- Parallel
- Outcome assessors and data analysts blinded
Primary result
ECV
Adjusted mean difference
−3.67 %
95% CI −5.33 to −2.01
P < 0.001
Canagliflozinvs Sitagliptin
adjusted mean difference −3.67 % (95% CI −5.33 to −2.01); P < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | Adjusted mean difference (ml) (95% CI) | P value | |
|---|---|---|---|
| Left ventricular end-diastolic volume · 26 weeks | −20.72 (−36.30 to −5.14) | P = 0.010 | |
| −40−20020Difference, ml (linear scale) |
| Outcome | Adjusted mean difference (mm) (95% CI) | P value | |
|---|---|---|---|
| Echocardiography-derived end-diastolic diameter · 26 weeks | −2.82 (−4.95 to −0.70) | P = 0.010 | |
| −6−4−202Difference, mm (linear scale) |
- HbA1c reduction · 26 weeks — Comparable HbA1c reductions in both groups
- both Δ 0.7% · inter-group p=0.972
Original publication
Canagliflozin attenuates CMR-quantified myocardial fibrosis in individuals with type 2 diabetes mellitus at high cardiovascular risk: a randomised open-label controlled trial. Diabetologia. Published 24 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →